IMUGENE LIMITED — Board/Management Information 2015

Feb 1, 2015

==> picture [174 x 57] intentionally omitted <==

Imugene Limited ACN 009 179 551

2 February 2015

Suite 1, 1233 High Street Armadale VIC 3142

Appointment of Charles Walker as Managing Director

Imugene Limited (ASX: IMU) CEO Charles Walker has been appointed as Managing Director and will join the company’s board with immediate effect.

Mr Walker’s election to the board comes after a successful six months since his appointment as CEO in August 2014. He has thus far overseen an important period for the company including the significant advancement of product development activities, in addition to overseeing the recent capital raising.

As announced upon his appointment as CEO, Charles has broad and successful experience across many aspects of the biotechnology and life sciences industry. He has operational and leadership experience, a strong capital markets track record as well as a detailed scientific understanding gained from his technical background in pharmacology.

Imugene’s Executive Chairman Paul Hopper said, “Charles has shown outstanding enthusiasm and endeavour since joining the company, working closely with our overseas based colleagues and he will be a welcome addition to the board.”

“His knowledge and experience in business and science are pivotal for Imugene and this appointment reflects his importance to the future of the company.”

Charles Walker Paul Hopper CEO Executive Chairman Tel: +61 (0) 4 5044 6990 Tel: +1 858 334 5820 (US) Cwalker[at]imugene.com Tel: +61 406 671 515 (Australia) www.imugene.com receptogen[at]earthlink.net

Media contact: Rudi Michelson Monsoon Communications +61 3 9620 3333 rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com